Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Coluracetam

From PsychonautWiki Archive
Revision as of 03:58, 11 July 2016 by >Catharsis (Tolerance and addiction potential)
Jump to navigation Jump to search

Template:Proofread

Coluracetam
Chemical Nomenclature
Common names Coluracetam
Systematic name N-(2,3-Dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxo-1-pyrrolidinyl)acetamide
Class Membership
Psychoactive class Nootropic
Chemical class Racetam
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 1 mg
Light 3 - 5 mg
Common 5 - 10 mg
Strong 10 - 20 mg
Heavy 20 mg +
Duration
Total 3 - 6 hours
Onset 15 - 30 minutes



Insufflated
Dosage
Threshold 1 mg
Light 2 - 5 mg
Common 5 - 10 mg
Strong 10 - 20 mg
Heavy 20 mg +
Duration
Total 3 - 6 hours
Onset 1 - 5 minutes






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Stimulants
Depressants
Dissociatives
Summary sheet: Coluracetam

Coluracetam (BCI-540), formerly (MKC-231) is a nootropic of the racetam family[1]. It was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the drug failed to reach the endpoints in its clinical trials, it was in-licensed by BrainCells Inc for investigations into major depressive disorder (MDD), which was preceded by being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California. Findings from phase IIa clinical trials have suggested that it would be a potential medication for comorbid major depressive disorder (MDD) with generalized anxiety disorder (GAD).

It is readily available and sold through online vendors as a dietary supplement in the United States. Dosages range nearly half of that of noopept, making it twice as potent while offering comparable benefit. Due to it's short acting and acute nature, the preferred ROA is generally insufflation, sublingual, or vaporising, though it is still active orally.

The active dose range of this compound is between 5 and 20 mg. This is much smaller than the comparable doses of the racetam class of drugs (piracetam, oxiracetam, phenylpiracetam, etc.). Dosages higher than 20mg do not appear to offer any additional benefit.

Chemistry

This chemistry section is incomplete.

You can help by adding to it.

Coluracetam, or 2-(2-oxopyrrolidin-1-yl)-N-(2, 3-dimethyl-5, 6, 7, 8-tetrahydrofuro2, 3-b quinolin-4-yl)acetoamide, is a synthetic racetam. A known metabolite is hydroxylated coluracetam on the 2-carbon of the pyrrolidinone backbone, it is sometimes referred to as M-MKC-231. It appears inactive on the main mechanism of action coluracetam is known for (increasing HACU).

Pharmacology

Coluracetam enhances high-affinity choline uptake (HACU),[2] which is the rate-limiting step of acetylcholine (ACh) synthesis. This process essentially allows acetylcholine to accumulate at higher levels than that which it otherwise would. As acetycholine is involved in the function of memory, this could potentially account for its nootropic effects.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

In comparison to the effects of other racetam nootropics such as noopept, this compound can be described as focusing primarily on physical stimulation over that of cognitive stimulation.

Sensory effects

A prominent experience amongst Coluracetam's effects is it's ability to enhance the immediate five senses.

Physical effects

  • Stimulation - The stimulation which Coluracetam presents can be considered as primarily subtle and short lasting, comparable to that of caffeine.

Cognitive effect

Toxicity and harm potential

The toxicity and long-term health effects of recreational coluracetam use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because coluracetam has very little history of human usage. Anecdotal evidence from people who have tried coluracetam within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed).

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

The chronic use of coluracetam can be considered as not addictive with a low potential for abuse. It does not seem to be capable of causing psychological dependence among certain users.

Tolerance to many of the effects of coluracetam develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). Coluracetam may presents cross-tolerance with [[Cross-tolerance::all racetam nootropics]], meaning that after the consumption of coluracetam certain nootropics such as noopept and piracetam may have a reduced effect.

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Coluractam, being a member of the racetam family, currently is legally available to buy and sell in most countries, but may still vary by region.

  • United Kingdom - This drug is illegal under the Psychoactive Substance Act, which came into effect on May 26th, 2016.[4]

See also

References

  1. Effect of the novel high affinity choline uptake enhancer 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b] quinolin-4-yl)acetoamide on deficits of water maze learning in rats. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/8740080
  2. MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice | http://link.springer.com/article/10.1007%2FBF01277590
  3. RESULTS FROM EXPLORATORY PHASE 2A TRIAL OF BCI-540 IN DEPRESSION WITH ANXIETY | https://web.archive.org/web/20111121081645/http://www.braincellsinc.com/wp-content/uploads/2010/06/BCI-PR-06142010.pdf
  4. Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted